Kymera Therapeutics (KYMR) Capital Expenditures Growth (1y) (2020 - 2026)
Kymera Therapeutics (KYMR) Capital Expenditures Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.62 Bn | 466.83 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 143.40% |
| 10 | Kymera Therapeutics | 10.85 Bn | 10.20 Bn | - | -7.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.07% |
| Dec 31, 2025 | 521.90% |
| Sep 30, 2025 | 195.77% |
| Jun 30, 2025 | -85.18% |
| Mar 31, 2025 | -93.69% |
| Dec 31, 2024 | 202.97% |
| Sep 30, 2024 | 98.72% |
| Jun 30, 2024 | -56.45% |
| Mar 31, 2024 | 84.63% |
| Dec 31, 2023 | 37.95% |
| Sep 30, 2023 | -1,285.96% |
| Jun 30, 2023 | 1,365.03% |
| Mar 31, 2023 | 731.74% |
| Dec 31, 2022 | -263.50% |
| Sep 30, 2022 | 307.19% |
| Jun 30, 2022 | 17.41% |
| Mar 31, 2022 | 193.90% |
| Dec 31, 2021 | 111.74% |
| Sep 30, 2021 | -87.30% |
| Jun 30, 2021 | -83.76% |